Submitted and under review
Berthold-Losleben M, Goksøyr IW, Kvam TM, Rog J, Stewart LH, Scarth S, Andreassen OA. Changes in wellbeing, self-compassion and alexithymia in a proof of principle trial with MDMA-assisted therapy for major depressive disorder. Under review.
Autran I, Kvam TM, Scarth S, Kaupang JS, Stewart LH, Clausen I, Dåstøl P, Andreassen OA, Berthold-Losleben M. Delayed response to maintenance intravenous ketamine in induction non-responders with treatment-resistant depression. Submitted.
2026
Kvam TM. A Clinical Trial of MDMA-Assisted Therapy for Major Depressive Disorder and Survey of Psychedelic Use. PhD thesis. Institute of Clinical Medicine, University of Oslo. 2026.
Kvam TM, Goksøyr IW, Stewart LH, Berthold-Losleben M, Autran I, Andreassen OA. Klinisk og ikke-klinisk bruk av MDMA. Tidsskrift for Den norske legeforening. 2026.
Stewart LH, Berthold-Losleben M, Kvam TM, Clausen I, Autran I, Jentoft van de Vooren IT, Andreassen OA. Transforming treatment-resistant depression care in Norway: public health reimbursement for off-label intravenous ketamine. Drug Science, Policy and Law. 2026.
Kvam TM, Goksøyr IW, Rog J, Autran I, Berthold-Losleben M, Andreassen OA. MDMA-assisted psychotherapy in major depression: critical considerations for clinical translation: commentary, Kvam et al. The British Journal of Psychiatry. 2026;1–2.
Berthold-Losleben M, Kvam TM, Andreassen OA, Goksøyr IW. Changes in wellbeing, self-compassion and alexithymia in a proof-of-principle trial with MDMA-assisted therapy for major depressive disorder. Neuroscience Applied, Vol. 5, Suppl. 1, 2026.
2025
Kvam TM, Goksøyr IW, Rog J, Jentoft van de Vooren IT, Stewart LH, Autran I, Berthold-Losleben M, Mørch-Johnsen L, Holst R, Røssberg JI, Clausen I, Andreassen OA. MDMA-assisted therapy for major depressive disorder: a seven-month follow-up proof-of-principle trial. Journal of Psychiatric Research. 2025;193:302–308.
Kvam TM, Goksøyr IW, Rog J, Jentoft van de Vooren IT, Stewart LH, Autran I, Berthold-Losleben M, Mørch-Johnsen L, Holst R, Clausen I, Andreassen OA. MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study. The British Journal of Psychiatry. 2025;227:783–789.
Berthold-Losleben M, Autran I, Folstad RLS, Römer B, Kvam TM, Jentoft van de Vooren IT, Stewart LH, Claussen I, Andreassen OA. Ketamine in treatment-resistant depression. Tidsskrift for Den norske legeforening. 2025;145.
Passie T, Loizaga-Velder A, Danforth A, Grob CS, Greer GR, Erritzoe D, Oehen P, Styk J, Schlichting M, Vermetten E, Goksøyr IW, Palenicek T, Mithoefer MC, Mithoefer A, Anderson B, Krediet E, Gasser P, Nielson EM, Gorman I, Phelps J, Belser AB, Guss J. A model training curriculum for psychedelic, psycholytic, and entactogen-assisted psychotherapy. Journal of Psychopharmacology. 2025.
Grønnerød C, Rønningen T, Haugsjå IR, Andersen KAA, Lindvall Dahlgren C, Kvam TM. Recreational MDMA use in Norway: results from an internet convenience sample. Frontiers in Psychiatry. 2025;16:1619676.
Tunstad PA, Kvam TM, Uthaug MV, Stewart LH, Andersen KAA, Grønnerød C. Contextual and experiential aspects of the psychedelic experience predicting improvement in subjective wellbeing: results from a Norwegian internet convenience sample. Frontiers in Pharmacology. 2025;16:1556299.
2024
Kvam TM, Goksøyr IW, Rog J, Jentoft van de Vooren IT, Stewart LH, Autran I, Berthold-Losleben M, Mørch-Johnsen L, Holst R, Clausen I, Andreassen OA. Exploration of MDMA-assisted therapy for major depressive disorder: a proof of principle study. Neuroscience Applied. 2024;3:104179.
2023
Kvam TM, Uthaug MV, Andersen KAA, Refsum BB, Tunstad PA, Stewart LH, Jacobsen HB, Grønnerød C. Epidemiology of classic psychedelic substances: results from a Norwegian internet convenience sample. Frontiers in Psychiatry. 2023;14:1287196.
Åman CMH, Kvam TM, Andreassen O, Rønsen AC. Ketamin har god effekt mot depresjon. Sykepleien.2023;111(93592):e-93592.
2022
Kvam TM, Goksøyr IW, Stewart LH, Repantis D, Røssberg JI, Andreassen OA. Study protocol for “MDMA-assisted therapy as a treatment for major depressive disorder: A proof of principle study”. Frontiers in Psychiatry.2022;13:954388.
2021
Kvam TM, Stewart LH, Blomkvist AW, Andreassen OA. Ketamine for depression: evidence and proposals for practice. Tidsskrift for Den norske legeforening. 2021;141.
Jacobsen HB, Stubhaug A, Holmøy B, Kvam TM, Reme SE. Have Norwegians tried psilocybin, and do they accept it as a medicine? Journal of Psychedelic Studies. 2021;5(1):33–36.
2020
Goksøyr IW, Kvam TM, Lund-Høie S, Stewart LH. Safety and efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in the treatment of post-traumatic stress disorder (PTSD): a systematic review. Tidsskrift for Norsk psykologforening. 2020;57(12):886–897.
2018
Kvam TM, Stewart LH, Andreassen OA. Psychedelic drugs in the treatment of anxiety, depression and addiction. Tidsskrift for Den norske legeforening. 2018;138(18).